During the past decade, Ospedale Sacro Cuore Don Calabria conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 15 clinical trials were completed, i.e. on average, 31.9% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 12 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ospedale Sacro Cuore Don Calabria" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Shire" with 5 trials sponsored, "Boston Scientific Corporation" with 4 trials sponsored, "Celgene" with 3 trials sponsored and "Fondazione Ricerca Traslazionale" with 3 trials sponsored. Other sponsors include 47 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale Sacro Cuore Don Calabria" #1 collaborator was "Clinical Research Technology S.r.l." with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 2 trials as a collaborator and "University of Padova" with 2 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Ospedale Sacro Cuore Don Calabria" are "Ulcerative Colitis" (10 trials), "Crohn Disease" (6 trials), "Crohn's Disease" (5 trials), "Breast Cancer" (4 trials) and "Heart Failure" (4 trials). Many other conditions were trialed in "Ospedale Sacro Cuore Don Calabria" in a lesser frequency.

Most popular intervention types in "Ospedale Sacro Cuore Don Calabria" are "Drug" (53 trials), "Device" (13 trials), "Other" (8 trials), "Procedure" (8 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Docetaxel" (4 trials), "Guselkumab" (4 trials), "Ontamalimab" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Ospedale Sacro Cuore Don Calabria" are 61 trials for "All" genders, 10 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Ospedale Sacro Cuore Don Calabria". undefined are not yet recruiting, 18 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Ospedale Sacro Cuore Don Calabria, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Ospedale Sacro Cuore Don Calabria, 0 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 9 trials that are defined as “Not Applicable".

Ospedale Sacro Cuore Don Calabria has several departments that took part in Clinical trials: "Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica" - 5 trials, "Ospedale Classificato Equiparato Sacro Cuore - Don Calabria; Dipartimento Oculistica" - 4 trials, "UOC Chirurgia Generale - Ospedale Sacro Cuore Don Calabria Negrar Verona" - 3 trials, "Ginecologia - IRCCS Ospedale Sacro Cuore Don Calabria" - 2 trials